Inspire Upper Airway Stimulation System
Commercial- Indications
- Obstructive sleep apnea
Company intelligence / Profile preview
Inspire Medical Systems has developed and commercialized the first and only FDA-approved, fully implanted neurostimulation system for moderate to severe obstructive sleep apnea. The therapy is supported by strong clinical data from nearly 6,000 patients worldwide and over 350 peer-reviewed publications. The company recently received FDA approval for its next-generation "Inspire V" system in August 2024 and continues to expand indications, including use in pediatric Down syndrome patients. Real-world evidence demonstrates compelling efficacy and safety outcomes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Inspire Medical Systems.